close

Main navigation

close
Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market

Europe GCSF-Filgastrim Market By Route of Administration (Intravenous, Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders and Others), By Country – Global Forecast to 2030

  • 20010

  • June 2021

  • 150

  • PDF

    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★

Select License

  • It allows one person, the buyer, to have sole right and access to the purchased report. Further distribution of product is strictly prohibited.
  • It allows the purchased product to be shared among 5 people within your organization at maximum.
  • It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.
Request sample

  • Marketresearch.Biz announces publication of its most recently generated research report titled, “Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market by Route of Administration (Intravenous & Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders & Other Applications), and by Country – Global Forecast to 2030”, which offers a holistic view of the Europe granulocyte colony stimulator factor (GCSF-filgastrim) market through systematic segmentation that covers every aspect of the target market. The Europe granulocyte colony stimulator factor (GCSF-filgastrim) market is projected to be US$ 2,251.8 Mn in 2020 to reach US$ 4,371.4 Mn by 2030 at a CAGR of 7.0%.

    Request Covid - 19 Impact

    Granulocyte colony-stimulating factor (GCSF) is a glycoprotein that simulates the bone marrow to produce granulocyte (a type of white blood cell) and stem cells and release them into the bloodstream.  A number of various tissues produce a type of colony stimulator factor, known as cytokine and hormone however, pharmaceutical analogs of this naturally occurring GCSF are filgrastim and lenograstim. Filgrastim is used for treatment of low neutrophil count, which me occur owing to various life risking diseases such as HIV/AIDs, following chemotherapy, or radiation poisoning among others.

    Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Revenue (US$ Mn), 2020–2030.The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is an important factor that is expected to fuel the revenue growth for the granulocyte-colony stimulating factor market in Europe. Also, the rising prevalence of cancer patients owing to unhealthily lifestyles, consumption of processed food, alcohol, and severe smoking habits is a factor that is expected to further bolster the projected financial growth of this given market over the coming years.

    Although the high costs associated with initial treatment of chemotherapy, coupled with the high cost of prophylaxis with G-CSF and stringent regulations of respective national authorities towards approval of biosimilar drugs, and high cost of development of this drug are also certain factors that are expected to hamper the revenue growth of this given market.

    Approval of biosimilar drugs such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper as compared to currently available drugs. These biosimilar drugs are expected to create financial growth opportunities for this given market over the forecast period. Moreover, rapid R&D has been witnessed in recent years for the development of new and effective drugs for GCSF that cost-effective as well, resulting in the increased success rate of clinical trials. This trend is expected to continue and further amplify the projected profit margins for this target market in Europe in the coming years.

    Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Attractiveness Analysis by Route of Administration, 2014–2030.Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Attractiveness Analysis by Route of Administration,

    The granulocyte colony stimulator factor (GCSF Filgastrim) market in Europe is segmented country-wise into Germany, UK, France, Russia, Italy, Spain, and Rest of Europe, respectively. Among these aforementioned Country, the markets in the Germany segment are expected to register the majority revenue shares of the granulocyte colony stimulator factor (GCSF filgastrim) market in Europe.

    The research report on the Europe granulocyte colony stimulator factor (GCSF-Filgastrim) market includes profiles of some of the major companies such as Novartis AG (Sandoz), Pfizer Inc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, Biocon Ltd, Dong-A Socio Holdings Co., Ltd, BioCad.

    Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market Segmentation Based on Route of Administration, Application, and Region

    Based on Route of Administration:

    • Intravenous
    • Subcutaneous

    Based on Application:

    • Oncological Diseases
    • Blood Disorders
    • Growth Hormone Deficiencies
    • Chronic and Autoimmune Disorders
    • Other Applications

    Based on Country:

    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Spain
    • Rest of Europe

    • Novartis AG (Sandoz)
    • Pfizer Inc
    • Amgen Inc
    • Teva Pharmaceutical Industries Ltd
    • Stada Arzneimittel AG
    • Dr. Reddy's Laboratories Ltd
    • Intas Pharmaceuticals Ltd
    • Biocon Ltd
    • Dong-A Socio Holdings Co. Ltd
    • BioCad.
    • Chapter 1 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Overview
      • 1.1 Introduction
      • 1.2 Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market Segmentation Based on Route of Administration, Application, and Region
      • 1.3 Drivers for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
      • 1.4 Restraints for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
      • 1.5 Opportunities for the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
      • 1.6 Trends in the Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market
      • 1.7 Drivers & Restraints Impact Analysis
      • 1.8 PESTE Analysis
      • 1.9 PORTER'S Five Forces Analysis
      • 1.10 Macro-Economic Factors
      • 1.11 The COVID-19 Heat Map: Impact on Industry Sectors
      • 1.12 Market Investment Feasibility Analysis
      • 1.13 COVID-19 Impact
      • 1.14 Clinical Trial Analysis of Granulocyte Colony Stimulator Factor
      • 1.15 Opportunity Map Analysis
        • 1.15.1 Optimistic Scenario
        • 1.15.2 Likely Scenario
        • 1.15.3 Conservative Scenario
      • 1.16 Opportunity Orbits
      • 1.17 Regional Market Share and BPS Analysis of Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market
    • Chapter 2 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Overview
      • 2.1 Europe Granulocyte Colony Stimulating Factor Market by Route of Administration
        • 2.1.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2014-2030)
        • 2.1.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Route of Administration in 2020
        • 2.1.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Route of Administration, 2014–2030
      • 2.2 Europe Granulocyte Colony Stimulating Factor Market by Application
        • 2.2.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2014-2030)
        • 2.2.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Application in 2020
        • 2.2.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Application, 2014–2030
      • 2.3 Europe Granulocyte Colony Stimulating Factor Market Outlook by Country
        • 2.3.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2014-2030)
        • 2.3.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Market Share by Country in 2020
        • 2.3.3 Europe Granulocyte Colony Stimulating Factor Market Attractiveness Analysis by Country, 2014–2030
      • 2.4 Europe Granulocyte Colony Stimulating Factor Market Outlook (2014–2030)
        • 2.4.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) (2014–2021)
        • 2.4.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) (2022–2030)
      • 2.5 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Country
        • 2.5.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2014–2021)
        • 2.5.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Country (2022–2030)
      • 2.6 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Route of Administration
        • 2.6.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2014–2021)
        • 2.6.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Route of Administration (2022–2030)
      • 2.7 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) by Application
        • 2.7.1 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2014–2021)
        • 2.7.2 Europe Granulocyte Colony Stimulating Factor Market Revenue (US$ Mn) Comparison by Application (2022–2030)
      • 2.8 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate Comparison 2015–2030
        • 2.8.1 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Country
        • 2.8.2 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Route of Administration
        • 2.8.3 Europe Granulocyte Colony Stimulating Factor Market Y-o-Y Growth Rate by Application
      • 2.9 Europe Granulocyte Colony Stimulating Factor Market Share Comparison 2014–2030
        • 2.9.1 Europe Granulocyte Colony Stimulating Factor Market Share by Country
        • 2.9.2 Europe Granulocyte Colony Stimulating Factor Market Share by Route of Administration
        • 2.9.3 Europe Granulocyte Colony Stimulating Factor Market Share by Application
    • Chapter 3 Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Company Profiles Overview
      • 3.1 Market Competition Scenario Analysis
      • 3.2 Overview of Major Market Players
      • 3.3 Company Profiles
        • 3.3.1 Novartis AG (Sandoz)
          • 3.3.1.1 Company Overview
          • 3.3.1.2 Business Description
          • 3.3.1.3 Product Portfolio (Sandoz)
          • 3.3.1.4 Key Financials
          • 3.3.1.5 Key Developments
          • 3.3.1.6 SWOT Analysis
        • 3.3.2 Pfizer Inc.
          • 3.3.2.1 Company Overview
          • 3.3.2.2 Business Description
          • 3.3.2.3 Product Portfolio
          • 3.3.2.4 Key Financials
          • 3.3.2.5 Key Developments
          • 3.3.2.6 SWOT Analysis
        • 3.3.3 Amgen Inc.
          • 3.3.3.1 Company Overview
          • 3.3.3.2 Business Description
          • 3.3.3.3 Product Portfolio
          • 3.3.3.4 Key Financials
          • 3.3.3.5 SWOT Analysis
        • 3.3.4 Teva Pharmaceutical Industries Ltd.
          • 3.3.4.1 Company Overview
          • 3.3.4.2 Business Description
          • 3.3.4.3 Product Portfolio
          • 3.3.4.4 Key Financials
          • 3.3.4.5 Key Developments
          • 3.3.4.6 SWOT Analysis
        • 3.3.5 Stada Arzneimittel AG
          • 3.3.5.1 Company Overview
          • 3.3.5.2 Business Description
          • 3.3.5.3 Product Portfolio
          • 3.3.5.4 Key Financials
          • 3.3.5.5 Key Developments
          • 3.3.5.6 SWOT Analysis
        • 3.3.6 Dr. Reddy's Laboratories Ltd.
          • 3.3.6.1 Company Overview
          • 3.3.6.2 Business Description
          • 3.3.6.3 Product Portfolio
          • 3.3.6.4 Key Financials
          • 3.3.6.5 Key Developments
          • 3.3.6.6 SWOT Analysis
        • 3.3.7 Intas Pharmaceuticals Ltd
          • 3.3.7.1 Company Overview
          • 3.3.7.2 Business Description
          • 3.3.7.3 Product Portfolio
          • 3.3.7.4 Key Financials
        • 3.3.8 Biocon Ltd.
          • 3.3.8.1 Company Overview
          • 3.3.8.2 Business Description
          • 3.3.8.3 Product Portfolio
          • 3.3.8.4 Key Financials
          • 3.3.8.5 Key Developments
        • 3.3.9 Dong-A Socio Holdings Co., Ltd
          • 3.3.9.1 Company Overview
          • 3.3.9.2 Business Description
          • 3.3.9.3 Product Portfolio
        • 3.3.10 BioCad
          • 3.3.10.1 Company Overview
          • 3.3.10.2 Business Description
          • 3.3.10.3 Product Portfolio
    • Chapter 4 Methodology and Data Source
      • 4.1 Methodology/Research Approach
        • 4.1.1 Market Size Estimation
      • 4.2 Market Breakdown and Data Triangulation
      • 4.3 Data Source
        • 4.3.1 Secondary Sources
        • 4.3.2 Primary Sources
    • Chapter 5 About Us
      • 5.1 Who we are:
    • Chapter 6 Disclaimer

  • Inquiry Form

    • I wish to see a sample of this report because.




    • Request for Customization
      message

    Why Choose Us

    • 360 Degree Approach
    • Growth Consulting
    • 24/7 Research Support
    • Comprehensive-Level of Customization
    • Comprehensive-Level of Customization
    • Competitive Intelligence
    • Single-Country/ Region Intelligence
    • Post-Sale Service Assistance
    • Access to Lead Analysts
    • Available in PDF, Excel, Word/ PPT

  • Secondary Research: An exhaustive secondary research is carried through both paid and free sources. It involves understanding critical data related to the market. Sources for secondary research include: Government websites Industry Associations Trade & Research Journals Company websites (annual reports, press releases, product brochures, etc. Import-Export Data Factiva, Morningstar, etc. Primary Research: Extensive interviews are held with key market participants through email interactions, online surveys, paid telephonic interviews, face-to-face interviews, etc., to gain a perspective on the market conditions, trends, developments, challenges, etc. Sources for primary research include: CXOs, Global Heads, VPs, Sales/ Purchase/ Product Managers of Key Market Players Distributors, Wholesalers, Retailers, Vendors of Products and Services End-Users belonging to each application industry

    Key Opinion Leaders (KOL) and Industry Experts: are credible, well-respected influencers in each industry with proven expertise and thought-leadership in the particular field, with a sound knowledge of the industry. We validate our initial research findings with these experts and try to understand their aspect to gain a deeper understanding of the current market trends, competitive landscape, market scope, disruptive technologies, etc. This helps us validate and strengthen our research findings, enhance the team’s expertise, and offer a clear understanding of the target market. All possible factors that influence the market are taken into consideration, such as: Capacity and Production Average Selling Price Total Customer Base Regulatory and Policy Changes Economic factors – Population, GDP, GDP Growth Rate, Inflation, Investments, etc

    Triangulation and Analysis: Post collection of the data from all sources and validation from industry experts, we triangulate the market with both a top-down and bottom-up approaches to eliminate any margin for errors. These methods aid us in estimating the market size, market share of manufacturers, regions segments, product segments and applications (end users). In-house Data Modeling Tool: our proprietary data modeling tool is designed to apply a combination of methods to provide accurate market size with the historical and forecasted data and growth rates. The percentage splits, Market Share (%), and breakdowns of the product segments are derived based on weightage assigned to each of the segments based on their utilization rate and average sale price. The regional splits of the overall target market and its sub-segments are based on the given product's percentage adoption or penetration rate in the respective region or country.

    Final Presentation: After the triangulation and analysis, we derive the market engineering data with the breakdown for all product segments, applications, and regions. The final report, along with the market dynamics, key USPs of the market are presented in a graphical and tabular format to provide a clear understanding to the client and provide a quick snapshot regarding the market, with the additional data to support the market estimations. .

RELATED REPORTS

OUR CLIENTS

Don't just take our word. We are trusted by these great companies!

MARKET RESEARCH REPORTS

MarketResearch.Biz (Powered by Prudour Pvt. Ltd.) delivers customized research solutions by actuating its broad spectrum of research methodologies, databases, and resources, and this is further strengthened by our global experience in syndicated and customized industry projects.

Our tailor-made research services include quick market scans, country reports, in-depth market analysis, competition monitoring, consumer research and satisfaction studies, supplier research, growth planning, and quite a lot more.

SHORT NAVIGATION

CONTACT US

Copyright © 2021 Prudour Private Limited. All Rights Reserved.

Powered by Pvt. Ltd.

Speak to Analyst
×

Request a call

person
phone
email
message

Customer Care

+1 (347) 796-4335